March 3, 2008-Fournier Laboratories Ireland Ltd (LFI) and Laboratoires Fournier S.A. (LFSA), wholly-owned subsidiaries of Solvay Pharmaceuticals, announced today that they have filed patent infringement court actions in the United States against Teva Pharmaceuticals.In January 2008 Fournier was informed by Teva Pharmaceuticals that the latter had filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval of a generic version of TriCor® (fenofibrate) 145mg NFE tablets in the U.S. As part of its application process, Teva submitted a Paragraph IV certification as required by law.
Solvay Pharmaceuticals is fully committed to its fenofibrate franchise and will vigorously protect the intellectual property for this product against any infringement.
No comments:
Post a Comment